Background

Traditional vaccine development platforms require months to culture pathogens and purify protein antigens. Responding promptly to urgent infectious disease outbreaks is inherently challenging due to these technological limitations. To overcome these limitations, messenger ribonucleic acid (mRNA) vaccine technology, which directly delivers genetic information into the body, has emerged as an alternative. The COVID-19 pandemic served as a critical turning point, leading to the widespread administration of this new platform to a large global population.

mRNA vaccines have proven their rapid design speed and ease of large-scale production, establishing themselves as a key component in pandemic response. However, with billions of doses administered, there is a growing need to objectively evaluate their actual efficacy and safety. Unscientific and indiscriminate information can undermine vaccine acceptance. This review article, published in the international medical journal 'The Lancet,' aims to answer these questions by comprehensively examining data from the molecular level to the real-world impact on public health.

Key Findings

The researchers first clearly demonstrated that mRNA vaccines do not enter the cell nucleus and cannot alter human DNA. The administered vaccine temporarily expresses antigen proteins in the cytoplasm and is then rapidly degraded. This molecular biological defense mechanism prevents any residual genetic material from remaining in the body and causing permanent effects. Lipid nanoparticle (LNP) delivery technology also appears to facilitate stable delivery to target cells and safe excretion from the body.

Analysis of data from large populations shows the strong preventive effect of the vaccine. The efficacy in preventing COVID-19 infection, preventing hospitalization, and reducing mortality was 87%, 93%, and 94%, respectively, between 14 and 42 days after vaccination. Although the immune response may decrease somewhat due to the emergence of variant viruses and the passage of time, booster doses have been shown to enhance immune protection.

The frequency of adverse events, which were a concern among the public, was also confirmed by objective clinical indicators. The incidence of myocarditis and pericarditis, which was rarely reported in young men, was found to be extremely low, contrary to concerns. The benefits of vaccination far outweigh the risk of myocarditis.

Significance and Prospects

This analysis is considered a milestone in confirming the potential for expansion of the mRNA platform beyond its role as an infectious disease control tool. The medical community is already actively applying this technology to the development of vaccines for influenza, respiratory syncytial virus (RSV), and human immunodeficiency virus (HIV). Furthermore, clinical trials are underway to develop personalized cancer vaccines that target cancer cell mutations in individual patients and therapies for autoimmune diseases.

There are also significant practical challenges to be overcome in the future. In particular, it is urgent to relax the ultra-low temperature storage requirements and reduce production costs to improve accessibility in low- and middle-income countries. To address the imbalance in supply between regions, it will be necessary to establish local manufacturing infrastructure and streamline regulatory approvals. The researchers predict that global health security can be achieved when technological improvements are combined with a well-established international cooperation system.